BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17176055)

  • 1. Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists.
    Sullivan SK; Brown MS; Gao Y; Loweth CJ; Lio FM; Crowe PD; Struthers RS; Betz SF
    Biochemistry; 2006 Dec; 45(51):15327-37. PubMed ID: 17176055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
    Betz SF; Reinhart GJ; Lio FM; Chen C; Struthers RS
    J Med Chem; 2006 Jan; 49(2):637-47. PubMed ID: 16420049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902.
    Struthers RS; Xie Q; Sullivan SK; Reinhart GJ; Kohout TA; Zhu YF; Chen C; Liu XJ; Ling N; Yang W; Maki RA; Bonneville AK; Chen TK; Bozigian HP
    Endocrinology; 2007 Feb; 148(2):857-67. PubMed ID: 17095587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
    Heitman LH; Ye K; Oosterom J; Ijzerman AP
    Mol Pharmacol; 2008 Jun; 73(6):1808-15. PubMed ID: 18344315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism.
    Sullivan SK; Hoare SR; Fleck BA; Zhu YF; Heise CE; Struthers RS; Crowe PD
    Biochem Pharmacol; 2006 Sep; 72(7):838-49. PubMed ID: 16930559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using structure-activity relationships, site-directed mutagenesis, and homology modeling.
    Betz SF; Lio FM; Gao Y; Reinhart GJ; Guo Z; Mesleh MF; Zhu YF; Struthers RS
    J Med Chem; 2006 Oct; 49(21):6170-6. PubMed ID: 17034124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization.
    Tucci FC; Zhu YF; Struthers RS; Guo Z; Gross TD; Rowbottom MW; Acevedo O; Gao Y; Saunders J; Xie Q; Reinhart GJ; Liu XJ; Ling N; Bonneville AK; Chen T; Bozigian H; Chen C
    J Med Chem; 2005 Feb; 48(4):1169-78. PubMed ID: 15715483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats.
    Anderes KL; Luthin DR; Castillo R; Kraynov EA; Castro M; Nared-Hood K; Gregory ML; Pathak VP; Christie LC; Paderes G; Vazir H; Ye Q; Anderson MB; May JM
    J Pharmacol Exp Ther; 2003 May; 305(2):688-95. PubMed ID: 12606616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Phe313 of the gonadotropin-releasing hormone (GnRH) receptor as a site critical for the binding of nonpeptide GnRH antagonists.
    Cui J; Smith RG; Mount GR; Lo JL; Yu J; Walsh TF; Singh SB; DeVita RJ; Goulet MT; Schaeffer JM; Cheng K
    Mol Endocrinol; 2000 May; 14(5):671-81. PubMed ID: 10809231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new gonadotrophin-releasing hormone partial agonists.
    Leaños-Miranda A; Ulloa-Aguirre A; Cervini LA; Janovick JA; Rivier J; Conn PM
    J Endocrinol; 2006 Jun; 189(3):509-17. PubMed ID: 16731782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors.
    Flanagan CA; Fromme BJ; Davidson JS; Millar RP
    Endocrinology; 1998 Oct; 139(10):4115-9. PubMed ID: 9751490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
    Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization and kinetic studies of an ancestral lamprey GnRH-III selective type II GnRH receptor from the sea lamprey, Petromyzon marinus.
    Silver MR; Sower SA
    J Mol Endocrinol; 2006 Jun; 36(3):601-10. PubMed ID: 16720727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor.
    Beckers T; Bernd M; Kutscher B; Kühne R; Hoffmann S; Reissmann T
    Biochem Biophys Res Commun; 2001 Dec; 289(3):653-63. PubMed ID: 11726197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists.
    Finch AR; Caunt CJ; Armstrong SP; McArdle CA
    Mol Endocrinol; 2010 Feb; 24(2):423-35. PubMed ID: 20009083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding.
    Hoffmann SH; ter Laak T; Kühne R; Reiländer H; Beckers T
    Mol Endocrinol; 2000 Jul; 14(7):1099-115. PubMed ID: 10894158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites.
    Plenge P; Gether U; Rasmussen SG
    Eur J Pharmacol; 2007 Jul; 567(1-2):1-9. PubMed ID: 17499240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.
    Chen C; Wu D; Guo Z; Xie Q; Reinhart GJ; Madan A; Wen J; Chen T; Huang CQ; Chen M; Chen Y; Tucci FC; Rowbottom M; Pontillo J; Zhu YF; Wade W; Saunders J; Bozigian H; Struthers RS
    J Med Chem; 2008 Dec; 51(23):7478-85. PubMed ID: 19006286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.